(2004). A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and Creactive protein following myocardial infarction: the CADET trial. J Thromb Haemost
(1984). Acceleration of thrombin antithrombin complex formation in rat hindquartes via heparin-like molecules bound to the endothelium.
(1989). An improved chemiluminescence assay suggests non nitric oxide mediated action of lysophoshatidylcholine and acetylcholine. Proc Soc Exp Biol Med
(2002). Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ
(2003). C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis. Circulation
(2002). Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel.
(1999). Chemokines and atherosclerosis. Atherosclerosis
(1993). Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication. Stroke
(2003). Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke
(1991). Dipyridamole potentiates the antiaggregating and vasodilator activity of nitric oxide.
(2000). Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells. Circulation
(2005). E, and Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a metaanalysis of individual patient data from randomized controlled trials. Stroke
(2004). Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.
(2000). Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis
(2005). Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and lecocyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemost
(2001). Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.
(1986). Effects of dipyridamole and low-dose aspirin therapy on platelet adhesion to vascular subendothelium.
(2001). Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin Cardiol
(2001). Effects of low-dose aspirin on serum Creactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay.
(1983). Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature
(1982). Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.
(2001). Inflammation and Thrombosis: The Clot Thickens. Circulation
(2004). Inflammation as a cardiovascular risk factor. Circulation
(1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev
(2001). Near-field amplification of antithrombotic effects of dipyridamole through vessel walls cells. Neurology
(1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.
(1998). p-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets
(1989). PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood
(2003). Plasma nitric oxide (nitrate/nitrite) levels in acute stroke and their relationship with severity and outcome.
(2003). Plasmatic nitric oxide, but not von Willebrand Factor, is an early marker of endothelial damage, in type 1 diabetes mellitus patients without microvascular complications.
(1993). Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler Thromb
(2004). Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis. Kidney Int
(1980). Platelet release reaction in vivo in patients with ischaemic heart disease after isometric exercise and its prevention with dipyridamole. Thromb Haemost
(2000). Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood
(1994). Role of platelet GpIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release. Life Sci
(2000). Role of von Willebrand factor in platelet thrombus formation. Ann Med
(2004). Soluble CD40 ligand and platelets: selfperpetuating pathogenic loop in thrombosis and inflammation?
(2002). Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis
(1995). von Willebrand factor, soluble Pselectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost